Crossmark Global Holdings Inc. Raises Holdings in Humana Inc. (NYSE:HUM)

Crossmark Global Holdings Inc. raised its position in Humana Inc. (NYSE:HUM) by 11.2% during the fourth quarter, HoldingsChannel reports. The firm owned 9,068 shares of the insurance provider’s stock after purchasing an additional 915 shares during the period. Crossmark Global Holdings Inc.’s holdings in Humana were worth $2,300,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Creative Financial Designs Inc. ADV raised its holdings in shares of Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 61 shares during the period. Atwood & Palmer Inc. acquired a new position in Humana in the 3rd quarter valued at about $29,000. Ashton Thomas Securities LLC purchased a new stake in shares of Humana in the 3rd quarter valued at approximately $31,000. Your Advocates Ltd. LLP increased its holdings in shares of Humana by 81.8% during the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares during the last quarter. Finally, LRI Investments LLC raised its position in shares of Humana by 1,021.4% during the 3rd quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock valued at $50,000 after buying an additional 143 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Insider Activity at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.32% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Leerink Partners lowered Humana from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $400.00 to $250.00 in a research report on Wednesday, October 2nd. TD Cowen boosted their price objective on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a report on Monday, November 4th. KeyCorp initiated coverage on shares of Humana in a research note on Friday, October 11th. They set a “sector weight” rating for the company. Piper Sandler boosted their price target on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Finally, Sanford C. Bernstein raised shares of Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price objective for the company in a research report on Tuesday, October 8th. Twenty investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $302.80.

Humana Price Performance

Shares of HUM opened at $293.22 on Friday. The firm has a market capitalization of $35.31 billion, a price-to-earnings ratio of 25.97, a PEG ratio of 2.15 and a beta of 0.55. The firm’s fifty day simple moving average is $273.81 and its 200-day simple moving average is $305.88. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $411.80. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. The company had revenue of $29.30 billion for the quarter, compared to analysts’ expectations of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. Equities analysts forecast that Humana Inc. will post 16.11 EPS for the current fiscal year.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.